WOBURN, Mass., Sept. 29 /PRNewswire/ -- SRU Biosystems, Inc. (“SRU” or “the Company”) announced today that the Company was recognized at this year’s Annual Meeting of the Society for Biomolecular Sciences (SBS 2006) with one of the conference’s “Best Poster” awards. SRU development scientists, in collaboration with researchers at GlaxoSmithKline’s Pharmaceutical Drug Discovery Center in Tres Cantos, Spain, presented a poster entitled, “BIND(TM) Microplate Label-free Biosensor Applied to Screening and Characterization of Small Molecule Ligands to Multiple Proteins.”
The work shows how BIND(TM) can be used to measure direct binding of small molecules to immobilized protein targets without labels. “The latest results utilized a validation library of greater than 1,400 diverse compounds to evaluate the use of the BIND(TM) Reader and 384-well BIND(TM) Biosensor plates to characterize a variety of small molecule-ligand interactions,” explained Lance Laing, PhD, who directed the research for SRU. “Two important aspects of the work included the ability to measure active protein in the presence of DMSO and to characterize small molecule binding for specificity, affinity and mechanism of action.”
Owen Dempsey, CEO of SRU Biosystems, stated, “We at SRU wish to thank the Society for Biomolecular Sciences for recognizing the importance of our work with GSK. It is an important confirmation that big booths and legions of lawyers are no substitute for strong science and systems that answer real-world questions posed to us by our customers around the world. Further, the work presented on the poster is just one of the unique applications that we have generated with our collaborators, and we look forward to publicizing the results of those efforts in the weeks and months ahead.
Mr. Dempsey continued, “SRU’s intellectual property portfolio encompasses all aspects of the BIND(TM) System, which we believe sets the standards in label-free detection. We want to focus on commercializing the BIND(TM) product line. From proteins to small molecules and cells, from 96-well biosensor plates for antibody affinity ranking to small molecule drug development in 384-well biosensor plates, BIND(TM) is an exciting tool in the hands of our customers.”
About SRU Biosystems
SRU Biosystems, Inc., is a life science company developing novel technologies for rapidly analyzing the interactions of cells, proteins, genomic, peptide, antibody or small molecule compound libraries against a wide range of biochemical targets. The patent protected BIND(TM) Technology represents a fundamental advance in the ability to monitor label-free biochemical interactions with high sensitivity and high throughput. SRU is incorporating its technology into microtiter plates, microarray slides and other industry standard formats to create sensitive and high throughput tools that can be used to answer important biological questions for biomedical research, pharmaceutical drug discovery and diagnostics.
For more information, please contact: Brant Binder, CFO Bbinder@srubiosystems.com +1 781-933-7255, ext. 202
SRU Biosystems, Inc.
CONTACT: Brant Binder, CFO of SRU Biosystems, +1 781-933-7255, ext. 202,Bbinder@srubiosystems.com
Web site: http://www.srubiosystems.com//
